Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 9465

This article opened with some fearful figures about cancer and its effect on people worldwide. But there’s reason to hope.

While the total number of new cancer cases and deaths continues to increase, the rates of cancer diagnoses and deaths decline each year — as absolute figures don’t account for rises in life expectancy, population growth, or aging populations. We’ve made great strides in understanding the disease and its various genetic and environmental origins. And events like Breast Cancer Awareness Month continue to educate the populace about the preventative measures available to them.

Thanks to scientists like those at the University of Basel in Switzerland, we may have more reasons to be hopeful very soon.

Read more

“Why are we impatient? It’s a heritage from our evolution,” says Marc Wittmann, a psychologist at the Institute for Frontier Areas of Psychology and Mental Health in Freiburg, Germany. Impatience made sure we didn’t die from spending too long on a single unrewarding activity. It gave us the impulse to act.

Not long ago I diagnosed myself with the recently identified condition of sidewalk rage. It’s most pronounced when it comes to a certain friend who is a slow walker. Last month, as we sashayed our way to dinner, I found myself biting my tongue, thinking, I have to stop going places with her if I ever want to … get there!

You too can measure yourself on the “Pedestrian Aggressiveness Syndrome Scale,” a tool developed by University of Hawaii psychologist Leon James. While walking in a crowd, do you find yourself “acting in a hostile manner (staring, presenting a mean face, moving closer or faster than expected)” and “enjoying thoughts of violence?”

Slowness rage is not confined to the sidewalk, of course. Slow drivers, slow Internet, slow grocery lines—they all drive us crazy. Even the opening of this article may be going on a little too long for you. So I’ll get to the point. Slow things drive us crazy because the fast pace of society has warped our sense of timing. Things that our great-great-grandparents would have found miraculously efficient now drive us around the bend. Patience is a virtue that’s been vanquished in the Twitter age.

Continue reading “Why Your Brain Hates Slowpokes” | >

Andrew Yang gives a dynamite interview on automation, UBI, and economic solutions to transitioning to the future.

Andrew Yang, award winning entrepreneur, Democratic Presidential candidate, and author of “The War on Normal People,” joins Ben to discuss the Industrial Revolution, Universal Basic Income, climate change, circumcision, and much more.

Check out more of Ben’s content on:

Continue reading “Andrew Yang | The Ben Shapiro Show Sunday Special Ep. 45” | >

A revolutionary 60-minute therapy for high blood pressure could allow patients to throw their tablets away for good.

The unlikely remedy involves blasting nerves in the kidneys with sound waves to stop them sending signals to the brain that drive up blood pressure.

It could slash the risk of heart attacks and strokes, two of Britain’s biggest killers.

Read more

More drugmakers are betting gene therapies will have a big impact on patients and profits, with Pfizer Inc. last month agreeing to collaborate with Paris-based Vivet Therapeutics on a treatment for a rare liver disorder. The U.S. Food and Drug Administration forecasts as many as 20 cell- and gene-therapy approvals each year by 2025. Doubts remain about whether the treatments will sustain their dramatic results, making it difficult to determine their value.

Dozens of revolutionary gene therapies that mend faulty strands of DNA are on their way, bringing the power to eliminate lethal childhood diseases, rare blood disorders and other severe illnesses.

Beneath the excitement about these potential cures lies an important catch: no one knows how much to charge for them.

The new therapies aim to fix the root causes of disease with a single dose, and if they can replace a lifetime of conventional costly drugs, they may slash overall spending, even at multimillion-dollar prices. Yet the prospect of high costs is already stirring pushback.

Continue reading “Gene Therapy Was Hailed as a Revolution. Then Came the Bill” | >